Total number of shares and voting rights in Zealand Pharma at February 28, 2021

Rhea-AI Summary

Zealand Pharma A/S has announced the total number of shares and voting rights as of February 28, 2021, in compliance with Danish Capital Markets Act. The company reported a total of 43,400,547 shares and voting rights, which corresponds to a nominal share capital of DKK 43,400,547. This announcement follows a previous update regarding an increase in share capital due to employee warrant exercises. Zealand Pharma specializes in innovative peptide-based medicines and has a strong pipeline, with several candidates in clinical development.

Positive

• Total shares and voting rights reached 43,400,547, indicating growth.
• Company has multiple drug candidates in late-stage development.
• Successful market presence with V-Go® insulin delivery product.

Negative

• None.

Company announcement – No. 11/ 2021

Total number of shares and voting rights in Zealand Pharma at February 28, 2021

Copenhagen, March 9, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. 

In Company announcement No. 4/2021 from February 1, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including February 28, 2021.

Date	Number of shares (nominal value of DKK 1 each)	Share capital (nominal value in DKK)	Number of voting rights
February 28, 2021	43,400,547	43,400,547	43,400,547

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go^®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.  

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com

Zealand Pharma Media Relations 
David Rosen
Argot Partners
media@zealandpharma.com

FAQ

What is the total number of shares for Zealand Pharma as of February 28, 2021?

Zealand Pharma reported a total of 43,400,547 shares as of February 28, 2021.

How many voting rights does Zealand Pharma have as of February 28, 2021?

As of February 28, 2021, Zealand Pharma has 43,400,547 voting rights.

What changes in share capital did Zealand Pharma announce recently?

Zealand Pharma announced an increase in share capital related to employee warrant exercises.

What are Zealand Pharma's main business focuses?

Zealand Pharma is focused on the discovery and development of innovative peptide-based medicines.

What notable product does Zealand Pharma market?

Zealand Pharma markets V-Go®, an all-in-one basal-bolus insulin delivery option for diabetes.